XML 109 R54.htm IDEA: XBRL DOCUMENT v3.6.0.2

Segment Information (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Revenue by product

	For the Years Ended December 31,
	2016												2015												2014
(In millions)	United States				Rest of World				Total				United States				Rest of World				Total				United States				Rest of World				Total
Multiple Sclerosis (MS):
TECFIDERA	$	3,169.4			$	798.7			$	3,968.1			$	2,908.2			$	730.2			$	3,638.4			$	2,426.6			$	482.6			$	2,909.2
AVONEX	1,675.3				638.2				2,313.5				1,790.2				840.0				2,630.2				1,956.7				1,056.4				3,013.1
PLEGRIDY	305.0				176.7				481.7				227.1				111.4				338.5				27.8				16.7				44.5
TYSABRI	1,182.9				780.9				1,963.8				1,103.1				783.0				1,886.1				1,025.1				934.4				1,959.5
FAMPYRA	—				84.9				84.9				—				89.7				89.7				—				80.2				80.2
ZINBRYTA	—				7.8				7.8				—				—				—				—				—				—
Hemophilia:
ELOCTATE	445.2				68.0				513.2				308.3				11.4				319.7				58.4				—				58.4
ALPROLIX	268.0				65.7				333.7				208.9				25.6				234.5				72.1				3.9				76.0
Other product revenues:
FUMADERM	—				45.9				45.9				—				51.4				51.4				—				62.5				62.5
SPINRAZA	4.6				—				4.6				—				—				—				—				—				—
BENEPALI	—				100.6				100.6				—				—				—				—				—				—
FLIXABI	—				0.1				0.1				—				—				—				—				—				—
Total product revenues	$	7,050.4			$	2,767.5			$	9,817.9			$	6,545.8			$	2,642.7			$	9,188.5			$	5,566.7			$	2,636.7			$	8,203.4

Geographic information

December 31, 2016 (In millions)	U.S.				Europe(1)				Germany				Asia				Other				Total
Product revenues from external customers	$	7,050.4			$	1,533.5			$	703.7			$	217.3			$	313.0			$	9,817.9
Revenues from anti-CD20 therapeutic programs	$	1,249.5			$	1.9			$	—			$	—			$	63.1			$	1,314.5
Other revenues from external customers	$	224.7			$	70.0			$	1.5			$	20.2			$	—			$	316.4
Long-lived assets	$	1,272.3			$	1,219.3			$	1.8			$	7.0			$	1.4			$	2,501.8
December 31, 2015 (In millions)	U.S.				Europe(1)				Germany				Asia				Other				Total
Product revenues from external customers	$	6,545.8			$	1,497.6			$	668.1			$	143.7			$	333.3			$	9,188.5
Revenues from anti-CD20 therapeutic programs	$	1,269.8			$	3.5			$	—			$	—			$	65.9			$	1,339.2
Other revenues from external customers	$	142.0			$	29.6			$	1.6			$	62.9			$	—			$	236.1
Long-lived assets	$	1,296.5			$	879.4			$	2.3			$	7.7			$	1.7			$	2,187.6
December 31, 2014 (In millions)	U.S.				Europe(1)				Germany				Asia				Other				Total
Product revenues from external customers	$	5,566.7			$	1,383.9			$	811.8			$	112.8			$	328.2			$	8,203.4
Revenues from anti-CD20 therapeutic programs	$	1,117.1			$	7.7			$	—			$	—			$	70.6			$	1,195.4
Other revenues from external customers	$	212.6			$	31.6			$	1.8			$	58.5			$	—			$	304.5
Long-lived assets	$	1,055.5			$	701.9			$	2.5			$	2.6			$	3.2			$	1,765.7

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration